Actively Recruiting
Study of Oral Tranexamic Acid After Primary Total Hip Replacement Surgery for Osteoarthritis
Led by Mayo Clinic · Updated on 2026-08-10
101
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating the effects of an extended oral Tranexamic Acid regimen in patients undergoing primary total hip arthroplasty for end-stage osteoarthritis. This study aims to assess how this treatment impacts patient-reported outcomes, time to independent walking, postoperative joint movement, swelling, changes in blood hemoglobin, and complications such as readmissions and reoperations within 90 days after surgery. The trial is a phase 4, randomized, single-blind study sponsored by Mayo Clinic. Participants are randomly assigned to either receive oral Tranexamic Acid or no additional intervention after surgery. Those in the treatment group will take a 1.95 g dose of oral Tranexamic Acid at four specific times after first walking post-surgery, and on postoperative days 1, 2, and 3. Patients receive spinal anesthesia and are discharged on postoperative day 1. During the study, participants will complete assessments including pain scores, hip function scores, and health surveys before surgery and at multiple points up to 12 weeks after surgery. Blood hemoglobin levels will be measured before discharge and on postoperative day 3. Researchers will monitor patients for recovery milestones like time to walk independently, as well as any complications through 90 days. Total participation spans from before surgery through 12 weeks of follow-up.
CONDITIONS
Brief Title
Postoperative Oral Tranexamic Acid in Patients Undergoing Primary Total Joint Arthroplasty
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here